I have been out of DVAX for a bit, but this is intriguing. Wall street loves restructuring when that restructuring eliminates big time expenses, and this certainly does. They mention they intend to sell SD-101. I wouldn't necessarily conclude that it's a failure yet. They could use ASCO to showcase positive results, on the heels of this announcement. Look at it this way, you announce the restructuring, you announce that its oncology assets are for sale. Would you the go to ASCO to present crap? 'Hey anyone out there want to buy this piece of crap drug?'
How embarrassing that would be. In other words, if the data is not good, why not announce the restructuring and the putting up the assets for sale after ASCO? But if you had intentions to sell, announce it now and showcase the positive results. I don't know but that would make sense to me. Something to think about anyway.
And now they are 100% focused on what they do best (if you can call their performance to date the best) which is Hepislav-B. Wall Street likes that too...focusing on your core capabilities.